Abstract: Objective: To observe curative effect of Lobaplatin plus 5-Fu/CF, the new antitumor platinum drugs, on advanced gastric or colorectal cancer. Methods: Thirty-one patients with advanced gastric or colorectal cancer were treated using the Lobaplatin/CF/5-Fu regimen. Results: The complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) rates were 3.2% (1/31), 19.4% (6/31), 45.2% (14/31) and 32.3% (10/31) respectively, with an overall response rate (CR+ PR) of 22.6% (7/31). The toxic effect was slight. Languor was the most common symptom in the grade-I to IV adverse reactions, accounting for 48.4% of the total cases. Other related symptoms included the anaemia (41.9%), anorexia (38.7%), leukocytopenia (35.5%), vomiting and nausea (32.3% ), thrombocytopenia (22.6%) and increase of ALT (16.1%). Conclusion: Lobaplatin is a new and safe antitumor platinum drug with a promising clinical effect, and it can try to be use on the patients who have received chemotherapy which conclude 5-Fu.